

EDURANT®

rilpivirine

AUSTRALIAN PRODUCT INFORMATION

1. NAME OF THE MEDICINE

Rilpivirine

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

EDURANT (rilpivirine) is available as 25 mg film-coated tablets. Each tablet contains rilpivirine hydrochloride equivalent to 25 mg rilpivirine.

Excipients with known effect

EDURANT tablets also contain lactose monohydrate. For a full list of excipients, see section 6.1 List of Excipients.

3. PHARMACEUTICAL FORM

EDURANT 25 mg tablets are white to off-white, film coated, round, biconvex, tablets of 6.4 mm, debossed with "TMC" on one side and "25" on the other side.

4. CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS

EDURANT, in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve adult patients with viral load \leq 100,000 copies/mL at baseline.

This indication is based on Week 48 safety and efficacy analyses from 2 randomised double-blind, controlled Phase III trials in treatment-naïve adult patients and on Week 96 safety and efficacy analyses from the Phase IIb trial TMC278-C204 in treatment-naïve adult patients (see section 5.1 Pharmacodynamic Properties, Clinical Trials).

4.2 DOSE AND METHOD OF ADMINISTRATION

Dosage (dose and interval)

The recommended dose of EDURANT in adults is one 25 mg tablet once daily taken orally with a meal (see section 5.2 Pharmacokinetic Properties).

Timing of dosing

If the patient misses a dose of EDURANT within 12 hours of the time it is usually taken, the patient should take EDURANT with a meal as soon as possible and then take the next dose of EDURANT at the regularly scheduled time. If a patient misses a dose of EDURANT by more than 12 hours, the patient should not take the missed dose, but resume the usual dosing schedule.

Dose adjustment with rifabutin coadministration

For patients concomitantly receiving rifabutin, the EDURANT dose should be increased to 50 mg (two tablets of 25 mg each) once daily, taken with a meal. When rifabutin co-administration is stopped, the EDURANT dose should be decreased to 25 mg once daily, taken with a meal (see section 4.5 Interactions with Other Medicines and Other Forms of Interactions).

Method of administration

EDURANT must always be given in combination with other antiretroviral medicinal products.

Special populations

<u>Elderly</u>

There is limited information regarding the use of EDURANT in patients >65 years of age (see sections 5.2 Pharmacokinetic Properties and 4.4 Special Warnings and Precautions for Use). No dose adjustment of EDURANT is required in elderly patients (see section 5.2 Pharmacokinetic Properties). EDURANT should be used with caution in this population (see sections 5.2 Pharmacokinetic Properties and 4.4 Special Warnings and Precautions for Use).

Paediatric population

The safety and efficacy of EDURANT in paediatric patients (<18 years of age) have not been established. Treatment with EDURANT is not recommended in these patients.

<u>Hepatic impairment</u>

No dose adjustment of EDURANT is required in patients with mild or moderate hepatic impairment (Child Pugh score A or B). EDURANT has not been studied in patients with severe hepatic impairment (Child Pugh score C). Therefore, EDURANT is not recommended in patients with severe hepatic impairment. EDURANT should be used with caution in patients with moderate hepatic impairment (see sections 5.2 Pharmacokinetic Properties and 4.4 Special Warnings and Precautions for Use).

<u>Renal impairment</u>

Rilpivirine has mainly been studied in patients with normal renal function. No dose adjustment of EDURANT is required in patients with mild or moderate renal impairment. In patients with severe renal impairment or end-stage renal disease, EDURANT should be used with caution. In patients with severe renal impairment or end-stage renal disease, the combination of EDURANT with a strong CYP3A inhibitor (e.g., ritonavir-boosted HIV protease inhibitor) should only be used if the benefit outweighs the risk (see section 5.2 Pharmacokinetic Properties).

Pregnancy and postpartum

The recommended dose of EDURANT in pregnant patients is one 25 mg tablet once daily taken orally with a meal. Lower exposures of rilpivirine were observed during pregnancy, therefore viral load should be monitored closely. Alternatively switching to another ART regimen could be considered (see sections 5.2 Pharmacokinetic Properties, Pregnancy and postpartum and 4.6 Fertility, Pregnancy and Lactation, Use in pregnancy).

4.3 CONTRAINDICATIONS

Hypersensitivity to rilpivirine or to any of the excipients.

EDURANT should not be co-administered with the following medicinal products, as significant decreases in rilpivirine plasma concentrations may occur (due to CYP3A enzyme induction or gastric pH increase), which may result in loss of therapeutic effect of EDURANT (see section 4.5 Interactions with Other Medicines and Other Forms of Interactions):

- the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, phenytoin
- the antimycobacterials, rifampicin, rifapentine
- proton pump inhibitors, such as omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole
- the glucocorticoid systemic dexamethasone, except as a single dose treatment
- St John's wort (*Hypericum perforatum*).

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Transmission of HIV

Patients should be advised that current antiretroviral therapy does not cure HIV. Reduction in the risk of sexual transmission is dependent on effective viral suppression. Appropriate precautions to prevent the sexual and bloodborne transmission of HIV should continue to be employed.

Virologic failure and development of resistance

In the pooled analysis from the Phase III trials to 96 weeks, patients treated with EDURANT with a baseline viral load > 100,000 HIV-1 RNA copies/mL had a greater risk of virologic failure (18.2% with EDURANT versus 7.9% efavirenz arm) compared to patients with a baseline viral load ≤ 100,000 HIV-1 RNA copies/mL (5.7% with EDURANT versus 3.6% efavirenz arm). The greater risk of virologic failure for patients in the EDURANT arm was observed in the first 48 weeks of these trials while low rates of virologic failure treatment arms were observed from week 48 to week 96 (see section 5.1 Pharmacodynamic Properties, Clinical Trials). Patients with a baseline viral load > 100,000 HIV-1 RNA copies/mL who experienced virologic failure exhibited a higher rate of treatment emergent resistance to the NNRTI class. More patients who failed virologically on EDURANT than who failed virologically on efavirenz developed lamivudine/emtricitabine associated resistance. This information should be taken into consideration when initiating therapy with EDURANT (see section 5.1 Pharmacodynamic Properties, Clinical Trials).

As with other antiretroviral medicinal products, resistance testing should guide the use of EDURANT.

Interactions with medicinal products

Caution should be given to prescribing rilpivirine with medicinal products that may reduce the exposure of rilpivirine. For information on interactions with medicinal products (see sections 4.3 Contraindications and 4.5 Interactions with Other Medicines and Other Forms of Interactions).

Immune reconstitution inflammatory syndrome

Immune reconstitution inflammatory syndrome has been reported in patients treated with combination antiretroviral therapy, including rilpivirine. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as *Mycobacterium avium* complex, cytomegalovirus, *Pneumocystis jiroveci* pneumonia, and tuberculosis), which may necessitate further evaluation and treatment (see section 4.8 Adverse Effects (Undesirable Effects)). Autoimmune disorders such as Graves' disease and autoimmune hepatitis have also been reported to occur in the setting of immune reconstitution inflammatory syndrome; however, the time to onset is more variable, and these events can occur many months after initiation of treatment (see section 4.8 Adverse Effects)).

Hepatic impairment

No dose adjustment of EDURANT is required in patients with mild or moderate hepatic impairment but caution is advised in patients with moderate hepatic impairment. EDURANT has not been studied in patients with severe hepatic impairment. Therefore, EDURANT is not recommended in patients with severe hepatic impairment (see sections 5.2 Pharmacokinetic Properties and 4.2 Dose and Method of Administration). EDURANT should be used with caution in patients with moderate hepatic impairment (see sections 5.2 Pharmacokinetic Properties and 4.2 Dose and Method of Administration).

CYP3A metabolism

Rilpivirine is a CYP3A substrate. It is possible that different populations of patients have faster or slower rilpivirine metabolism because of the various isoenzymes within the CYP3A system.

Use in the elderly

There is limited information regarding the use of EDURANT in patients> 65 years of age (see section 5.2 Pharmacokinetic Properties). No dose adjustment of EDURANT is required in elderly patients. EDURANT should be used with caution in this population (see sections 5.2 Pharmacokinetic Properties and 4.2 Dose and Method of Administration).

Paediatric use

Treatment with EDURANT is not recommended in paediatric patients (<18 years of age) due to insufficient data in this patient population.

Effects on laboratory tests

No data available.

4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

Medicinal products that affect rilpivirine exposure

Rilpivirine is primarily metabolised by cytochrome P450 CYP3A, and medicinal products that induce or inhibit CYP3A may thus affect the clearance of rilpivirine. Co-administration of EDURANT and medicinal products that induce CYP3A may result in decreased plasma concentrations of rilpivirine which could potentially reduce the therapeutic effect of rilpivirine. Co-administration of EDURANT and medicinal products that inhibit CYP3A may result in increased plasma concentrations of rilpivirine.

Medicines that suppress gastric acid

Use of proton pump inhibitors is contraindicated as significant decreases in EDURANT plasma concentrations may occur (see section 4.3 Contraindications).

The combination of EDURANT and H_2 -receptor antagonists or antacids should be used with caution as co-administration may cause significant decreases in rilpivirine plasma concentrations (gastric pH increase). Co-administration of EDURANT with medicinal products that increase gastric pH may result in decreased plasma concentrations of rilpivirine which could potentially reduce the therapeutic effect of rilpivirine. H_2 -receptor antagonists should only be administered at least 12 hours before or at least 4 hours after EDURANT and antacids should only be administered at least 2 hours before or at least 4 hours after EDURANT.

Medicinal products that are affected by the use of rilpivirine

EDURANT at a dose of 25 mg q.d. is not likely to have a clinically relevant effect on the exposure of medicinal products metabolised by CYP enzymes.

Established and theoretical interactions with selected antiretrovirals and non-antiretroviral medicinal products are listed below in Table 1 and Table 2, respectively.

Interactions between rilpivirine and co-administered medicinal products are listed in the tables below (increase is indicated as " \uparrow ", decrease as " \downarrow ", no change as " \leftrightarrow ", not applicable as "NA", once daily as "q.d." and twice daily as "b.i.d.").

Co-administered medicinal product	Dose of co-administered medicinal product	Medicinal product assessed	C _{max}	AUC	C _{min}
HIV NUCLEOSIDE OR	NUCLEOTIDE REVE	RSE TRANSCRI	PTASE INHI	BITORS (N	RTIs/N[t]RTIs)
Didanosine*#	400 mg q.d.	didanosine	\leftrightarrow	↑ 12%	NA
		rilpivirine	\leftrightarrow	\leftrightarrow	\leftrightarrow
	No dose adjustmer didanosine. Didano least two hours bef be administered wi	osine should be action of a contract of the should be actioned by a contract for a contract of the should be ac	ministered o	n an empty	stomach and a
Tenofovir disoproxil	300 mg q.d.	tenofovir	↑ 19%	↑ 23%	↑ 24%
fumarate*#		all a la dada a			
fumarate*#		rilpivirine	\leftrightarrow	\leftrightarrow	\leftrightarrow

 Table 1: Drug interactions – Rilpivirine co-administered with antiretroviral and antiviral medicinal products

Co-administered medicinal product	Dose of co-administered medicinal product	Medicinal product assessed	C _{max}	AUC	C _{min}
Other NRTIs (abacavir, emtricitabine, lamivudine, stavudine and zidovudine)	Based on the differe NRTIs, no clinically these medicinal pro	relevant drug-dru	ug interaction		
HIV NON-NUCLEOSIDE	REVERSE TRANSC	RIPTASE INHIE	BITORS (NN	RTIs)	
NNRTIs (delavirdine, efavirenz, etravirine, nevirapine)	It is not recommend	ed to co-adminis	ter EDURAN	IT with NNI	RTIs.
HIV PROTEASE INHIBI	FORS (PIs) - with co	-administration	of low dose	ritonavir	
Darunavir/ritonavir*#	800/100 mg q.d.	darunavir	\leftrightarrow	\leftrightarrow	↓ 11%
	Concomitant use of increase in the plass enzymes). No dose co-administered with	na concentratior adjustment is re	ns of rilpiviring quired when	e (inhibitior	cause an of CYP3A
Lopinavir/ritonavir (soft gel capsules)*#	400/100 mg b.i.d. Concomitant use of increase in the plass enzymes). No dose co-administered with	na concentratior adjustment is re	ns of rilpiviring quired when	e (inhibitior	n of CYP3A
Other boosted PIs (atazanavir/ritonavir, fosamprenavir/ritonavir , saquinavir/ritonavir, tipranavir/ritonavir)	Concomitant use of the plasma concent EDURANT is not ex co-administered PIs	rations of rilpivirii pected to affect t	ne (inhibition	of CYP3A	enzymes).
HIV PROTEASE INHIBI	FORS (PIs) - without	co-administrat	ion of low d	ose ritona	vir
Unboosted PIs (atazanavir, fosamprenavir, indinavir, nelfinavir)	Concomitant use of the plasma concentr EDURANT is not ex co-administered PIs	ations of rilpivirir pected to affect t	ne (inhibition	of CYP3A	enzymes).
CCR5 ANTAGONISTS					
Maraviroc	No clinically relevan co-administered with		action is expe	ected wher	EDURANT is
IV INTEGRASE STRAI	ND TRANSFER INHI	BITORS			
Cabotegravir	30 mg q.d.	cabotegravir	\leftrightarrow	\leftrightarrow	\leftrightarrow
	No dose adjustment cabotegravir.	rilpivirine is required when	↔ n EDURANT	↔ is co-admi	↓ 8% [¥] nistered with
Raltegravir*	400 mg b.i.d.	raltegravir	↑ 10%	↑ 9%	↑ 27%
	No dose adjustment raltegravir.	rilpivirine is required wher	↔ n EDURANT	↔ is co-admi	\leftrightarrow nistered with

Co-administered medicinal product			C _{max}	AUC	C _{min}
Ribavirin	No clinically relevant co-administered with		ction is exp	ected when	EDURANT is
predicted. This interaction study h maximal effect on the c EDURANT 25 mg q.d.	n EDURANT and the drug was as been performed with a dose co-administered drug. The dosi erved concentration at end of d /al)	e higher than the recong recommendation is	mmended dos applicable to	e for EDURAN the recommer	IT assessing the ided dose of
Table 2: Drug interac products	ctions – Rilpivirine co-a	administered wit	h non-antir	etroviral m	nedicinal
Co-administered medicinal product	Dose of co-administered medicinal product	Medicinal product assessed	C _{max}	AUC	C _{min}
ANTIARRHYTHMICS					
Digoxin*	0.5 mg singledose No dose adjustment is i	digoxin required when EI	↔ OURANT is (↔ co-administ	NA ered with digoxin
ANTIDIABETICS					
Metformin*	850 mg single dose No dose adjustment is metformin.	metformin required when EI	↔ DURANT is (↔ co-administ	NA ered with
ANTICONVULSANT	6				
Carbamazepine Oxcarbazepine Phenobarbital Phenytoin	EDURANT should not b co-administration may o concentrations (induction therapeutic effect of ED	cause significant on of CYP3A enz	decreases i	n rilpivirine	plasma
AZOLE ANTIFUNGA					
Ketoconazole*#	400 mg q.d.	ketoconazole rilpivirine	↔ ↑ 30%	↓ 24% ↑ 49%	↓ 66% ↑ 76%
Fluconazole Itraconazole Posaconazole Voriconazole	Concomitant use of ED increase in the plasma enzymes). No dose adj with azole antifungal ag	concentrations of ustment is require	[;] rilpivirine (i	nhibition of	CYP3A

NTIMYCOBACTE					
Rifabutin*	300 mg q.d.†	rifabutin	\leftrightarrow	\leftrightarrow	\leftrightarrow
		25- <i>O</i> -desacetyl- rifabutin	\leftrightarrow	\leftrightarrow	\leftrightarrow
	300 mg q.d.	rilpivirine (25 mg q.d.)	↓ 31%	↓ 42%	↓ 48%
	300 mg q.d.	rilpivirine (50 mg q.d.)	↑ 43%	↑ 16%	\leftrightarrow
		(as compared to	25 mg q.d.	rilpivirine a	lone)
	Concomitant use of E rilpivirine plasma cond in loss of therapeutic EDURANT with rifabu once daily to 50 mg o EDURANT dose shou	centrations (induction effect of EDURANT. itin, the EDURANT d nce daily. When rifab	n of CÝP3A Throughou ose should outin co-adr	enzymes). t co-admini be increase ministration	This may resu stration of ed from 25 mg
Rifampicin* [#]	600 mg q.d.	rifampicin	\leftrightarrow	\leftrightarrow	NA
		25-desacetyl-rif ampicin	\leftrightarrow	↓9%	NA
		rilpivirine	↓ 69%	↓ 80%	↓ 89%
Rifapentine	EDURANT should not co-administration may concentrations (induc therapeutic effect of E	/ cause significant de tion of CYP3A enzyn	creases in	rilpivirine p	lasma
IACROLIDE ANTI	BIOTICS				
Clarithromycin Erythromycin Troleandomycin	Concomitant use of E troleandomycinmay ca (inhibition of CYP3A e azithromycin should b	ause an increase in t enzymes). Where pos	he plasma	concentrati	ons of rilpivirine
LUCOCORTICOI	DS				
Dexamethasone (systemic)	EDURANT should not co-administration may concentrations (induc therapeutic effect of E for long-term use.	/ cause significant de tion of CYP3A enzyn	ecreases in nes). This r	rilpivirine p nay result ir	lasma າ loss of
ROTON PUMP IN	HIBITORS				
Omeprazole*#	20 mg q.d.	omeprazole	↓ 14%	↓ 14%	NA
		rilpivirine	↓ 40%	↓ 40%	↓ 33%
Lansoprazole Rabeprazole Pantoprazole Esomeprazole	EDURANT should not co-administration may concentrations (gastri of EDURANT.	/ cause significant de	creases in	rilpivirine p	lasma
2-RECEPTOR AN					
Famotidine* [#]	40 mg single dose taken 12 hours before rilpivirine	rilpivirine	\leftrightarrow	↓9%	NA
	40 mg single dose taken 2 hours before rilpivirine	rilpivirine	↓ 85%	↓ 76%	NA
	40 mg single dose taken 4 hours	rilpivirine	↑ 21%	↑ 13%	NA
	after rilpivirine				

ANTACIDS					
Antacids (e.g., aluminium or magnesium hydroxide, calcium carbonate)	The combination of ED co-administration may concentrations (gastric at least 2 hours before	cause significant de pH increase). Anta	ecreases in icids should	rilpivirine p d only be ac	olasma
NARCOTIC ANALGI	ESICS				
Methadone*	60-100 mg q.d., individualised dose	R(-) methadone S(+) methadone	↓ 14% ↓ 13%	↓ 16% ↓ 16%	↓ 22% ↓ 21%
	No dose adjustments a with EDURANT. Howe maintenance therapy n	ver, clinical monitor	ing is recor	nmended a	s methadone
HERBAL PRODUCT	S				
St John's wort (Hypericum perforatum)	EDURANT should not St John's wort (<i>Hyperic</i> significant decreases in enzymes). This may re	<i>cum perforatum</i>) as n rilpivirine plasma o	co-adminis	stration may	/ cause ion of CYP3A
ANALGESICS					
Acetaminophen*#	500 mg single dose	acetaminophen	\leftrightarrow	\leftrightarrow	NA
(paracetamol)		rilpivirine	\leftrightarrow	\leftrightarrow	↑ 26%
	No dose adjustment is acetaminophen (parac		JRANT is c	o-administe	ered with
	CONTRACEPTIVES				
Ethinylestradiol*	0.035 mg q.d.	ethinylestradiol	↑ 17%	\leftrightarrow	\leftrightarrow
Norethindrone*	1 mg q.d.	norethindrone	\leftrightarrow	\leftrightarrow	\leftrightarrow
	No dose adjustment is estrogen- and/or proge				RANT and
HMG CO-A REDUCT	ASE INHIBITORS				
Atorvastatin*#	40 mg q.d.	atorvastatin	↑ 35%	\leftrightarrow	↓ 15%
		rilpivirine	↓ 9%	\leftrightarrow	\leftrightarrow
Fluvastatin Lovastatin Pitavastatin Pravastatin Rosuvastatin Simvastatin	No dose adjustment is HMG Co-A reductase i		JRANT is c	o-administe	ered with an
	ASE TYPE 5 (PDE-5) IN	IHIBITOR			
Sildenafil*#	50 mg single dose	sildenafil	\leftrightarrow	\leftrightarrow	NA
	00g 0g.0	rilpivirine	\leftrightarrow	\leftrightarrow	\leftrightarrow
Vardenafil Tadalafil	No dose adjustment is PDE-5 inhibitor.	•			
 The interaction bet interactions shown This interaction stu assessing the max 	tween rilpivirine and the dru	h a dose higher than t	the recomme	ended dose f	for EDURANT

recommended dose of rilpivirine 25 mg q.d.

[†] This interaction study has been performed with a dose higher than the recommended dose for EDURANT.

QT prolonging drugs

There is limited information available on the potential for a pharmacodynamic interaction between rilpivirine and other medicinal products that prolong the QTc interval of the electrocardiogram. In a study of healthy subjects, supratherapeutic doses of rilpivirine (75 mg q.d. and 300 mg q.d.) have been shown to prolong the QTc interval of the electrocardiogram (see section 5.1 Pharmacodynamic Properties). EDURANT at the recommended dose of 25 mg once daily is not associated with a clinically relevant effect on QTc. EDURANT should be used with caution when co-administered with a medicinal product with a known risk of Torsade de Pointes.

4.6 FERTILITY, PREGNANCY AND LACTATION

Effects on fertility

No human data on the effect of rilpivirine on fertility are available. In a study conducted in rats, there were no effects on mating or fertility with rilpivirine up to 400 mg/kg/day, a dose of rilpivirine that showed maternal toxicity. This dose is associated with an exposure that is approximately 40 times higher than the exposure in humans at the recommended dose of 25 mg q.d.

Use in pregnancy - Category B1

There are no well controlled clinical or pharmacokinetic studies with rilpivirine in pregnant women. Placental transfer of rilpivirine or its metabolites from dam to fetus was demonstrated in rats. Studies in animals have shown no evidence of relevant embryonic or foetal toxicity or an effect on reproductive function. There was no clinically relevant teratogenicity with rilpivirine in rats and rabbits. The exposures at the embryo-foetal No Observed Adverse Effects Levels (NOAELs) in rats and rabbits were respectively 15 and 71 times higher than the exposure in humans at the recommended dose of 25 mg q.d.

To monitor maternal-fetal outcomes of pregnant women, an Antiretroviral Pregnancy Registry has been established (http://www.apregistry.com). This is a voluntary prospective, exposureregistration, observational study designed to collect and evaluate data on the outcomes of pregnancy exposures to antiretroviral products. For rilpivirine, sufficient first trimester exposures are available to allow detection of at least a two-fold increase in risk of overall birth defects. No such increases have been detected to date.

Rilpivirine in combination with a background regimen was evaluated in a clinical trial of 19 pregnant women during the second and third trimesters, and postpartum. The pharmacokinetic data demonstrate that total exposure (AUC) to rilpivirine as a part of an antiretroviral regimen was approximately 30% lower during pregnancy compared with postpartum (6-12 weeks). Virologic response was preserved throughout the trial period. No mother to child transmission occurred in all 10 infants born to the mothers who completed the trial and for whom the HIV status was available. Rilpivirine was well tolerated during pregnancy and postpartum. There were no new safety findings compared with the known safety profile of rilpivirine in HIV-1 infected adults (see section 5.2 Pharmacokinetic Properties, Pregnancy and postpartum).

EDURANT should be used during pregnancy only if the potential benefit justifies the potential risk. Contraception in males and females

A trial to investigate the effect of EDURANT when co-administered with oral contraceptives demonstrated that EDURANT is unlikely to decrease the effectiveness of oral contraceptives. EDURANT and estrogen- and/or progesterone-based contraceptives can be used together without dose adjustments (see section 4.5 Interactions with other medicines and other forms of interactions).

Use in lactation

It is not known whether rilpivirine is secreted in human milk. In nonclinical studies, rilpivirine was detected in the plasma of suckling rats following maternal dosing. Because of both the potential for HIV transmission and the potential for adverse events in nursing infants, mothers should be instructed not to breastfeed if they are receiving EDURANT.

4.7 EFFECT ON ABILITY TO DRIVE AND USE MACHINES

EDURANT has no or negligible influence on the ability to drive and use machines.

4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

Adverse effects from clinical trials

The safety assessment is based on the 96 week pooled data from 1368 patients in the Phase III controlled trials TMC278 C209 (ECHO) and TMC278 C215 (THRIVE) in antiretroviral treatment naïve HIV 1 infected adult patients, 686 of whom received EDURANT (25 mg q.d.) (see section 5.1 Pharmacodynamic Properties, Clinical Trials). The median duration of exposure for patients in the EDURANT and efavirenz arms was 104.3 and 104.1 weeks, respectively. Most adverse reactions (ARs) occurred in the first 48 weeks of treatment.

In the Phase III controlled trials ECHO and THRIVE to 96 weeks, the most frequently reported ARs (≥ 2%) that were at least grade 2 in severity were depression, headache, insomnia, transaminases increased and rash (see Table 3 for the complete list of ARs). Please note "transaminases increased" includes preferred terms "AST increased", "ALT increased", "Liver function test abnormal", "transaminases increased", "ALT abnormal", "hepatic enzyme increased" and hypertransaminasemia.

The majority of the ARs reported during treatment with EDURANT 25 mg once daily were grade 1 to 2 in severity. Grade 3 or 4 ARs were reported in 3.6% and 5.9% of the EDURANT and efavirenz treated patients, respectively. The most common (reported in more than 1 patient in the EDURANT arm) grade 3 or 4 ARs were transaminases increased (1.6% in the EDURANT arm and 2.9% in the efavirenz arm), depression (0.7 and 0.7% respectively), abdominal pain (0.4% and 0.1% respectively), dizziness (0.3% and 0.4% respectively) and rash (0.3% and 0.6% respectively). 1.7% of patients in the EDURANT arm discontinued treatment due to ARs compared to 4.0% of patients in the efavirenz arm. In the EDURANT arm, all ARs leading to discontinuation had an incidence < 0.5%. In the efavirenz arm, the most common ARs leading to discontinuation were rash (1.5%), transaminases increased (0.7%), depression (0.6%) and abnormal dreams (0.6%).

The most common ARs were identified in the system organ classes (SOC) of nervous system disorders (25.7% in the EDURANT arm and 42.8% in the efavirenz arm), psychiatric disorders (23.6% in the EDURANT arm and 26.4% in the efavirenz arm) and gastrointestinal disorders (24.1% in the EDURANT arm and 22.1% in the efavirenz arm). The difference between EDURANT and the efavirenz arms observed in the SOC nervous system disorders was mainly due to the difference in dizziness experienced by patients.

ARs of at least moderate intensity (≥ grade 2) reported in adult patients treated with EDURAN	ΝT
are summarised in Table 3. The ARs are listed by system organ class (SOC) and frequency.	

	Pooled data from the week 96 a	nalysis of the Phase III ECHO			
System Organ Class (SOC)	and THRIVE trials				
Adverse reaction, %	rilpivirine + BR N=686	efavirenz + BR N=682			
Skin and subcutaneous tissue	2.3%	9.5%			
disorders					
Rash ^{*#}	2.3%	9.5%			
Psychiatric disorders	9.3%	9.7%			
Depression	4.1%	3.2%			
Insomnia	3.5%	3.5%			
Abnormal dreams* [†]	1.6%	4.0%			
Sleep disorders	1.3%	0.9%			
Depressed mood	0.4%	0.3%			
Nervous system disorders	4.5%	10.7%			
Headache*	3.5%	3.8%			
Dizziness*#	1.0%	6.7%			
Somnolence	0.7%	1.3%			
Gastrointestinal disorders	3.8%	5.6%			
Abdominal pain	2.0%	1.9%			
Nausea*	1.3%	2.8%			
Vomiting	1.0%	2.1%			
Abdominal discomfort	0.4%	0.1%			
Metabolism and nutrition disorders	1.2%	0.6%			
Decreased appetite	1.2%	0.6%			
General disorders and administration site conditions	1.6%	2.1%			
Fatigue	1.6%	2.1%			
Investigations	2.8%	4.0%			
Transaminases increased	2.8%	4.0%			
14 230022	Page 10	EDURANT (250116) AR			

BR=background regimen

N=total number of patients per treatment group

* Treatment comparison was pre-specified for these ARs (Fisher's Exact Test)

- [†] p-value < 0.01
- [#] p-value < 0.0001

No new AR terms were identified in adult patients in the Phase III ECHO and THRIVE trials between 48 weeks and 96 weeks nor in the Phase IIb TMC278-C204 trial through 240 weeks.

Laboratory abnormalities

Selected treatment emergent clinical laboratory abnormalities (grade 3 or grade 4), reported in EDURANT-treated patients are shown in Table 4.

Table 4: Selected treatment emergent laboratory abnormalities (grade 3 or grade 4) observed in antiretroviral treatment-naïve HIV-1 infected adult patients

Laboratory parameter		Pooled data from the week 96 analysis of the Phase III ECHO and THRIVE trials				
abnormality, n/N (%)	DAIDS toxicity range	rilpivirine + BR N=686	efavirenz + BR N=682			
HEMATOLOGY						
Decreased hemoglobin	< 4.5 mmol/L < 74 g/L	1/685 (0.1%)	4/669 (0.6%)			
Decreased platelet count	< 49999/mm ³ < 49999 x 10 ⁹ /L	1/684 (0.1%)	2/667 (0.3%)			
Decreased white blood cell count	< 1499/mm ³ < 1.499 10 ⁹ /L	8/685 (1.2%)	7/669 (1.0%)			
BIOCHEMISTRY						
Increased creatinine	> 1.8 x ULN	1/685 (0.1%)	1/670 (0.1%)			
Increased AST	> 5.0 x ULN	16/685 (2.3%)	22/669 (3.3%)			
Increased ALT	> 5.0 x ULN	11/685 (1.6%)	25/670 (3.7%)			
Increased bilirubin	> 2.5 x ULN	5/685 (0.7%)	2/670 (0.3%)			
Increased pancreatic amylase	> 2 x ULN	26/685 (3.8%)	32/670 (4.8%)			
Increased lipase	> 3 x ULN	6/685 (0.9%)	11/670 (1.6%)			
Increased total cholesterol (fasted)*	> 7.77 mmol/L > 300 mg/dL	1/685 (0.1%)	22/669 (3.3%)			
Increased LDL cholesterol (fasted)*	≥ 4.91 mmol/L ≥ 191 mg/dL	10/685 (1.5%)	35/666 (5.3%)			
Increased Triglycerides (fasted)*	≥ 8.49 mmol/L ≥ 751 mg/dL	4/685 (0.6%)	22/669 (3.3%)			

BR=background regimen; ULN=upper limit of normal

N=number of patients per treatment group

* $p \le 0.001$ according to Fisher's Exact test (difference in grade 3 plus 4 abnormalities between the two treatment groups). Note: Percentages were calculated for the number of patients with results for the analyte.

Adrenal function

In the pooled Phase III trials, at Week 96, the overall mean change from baseline in basal cortisol was-19.1 nmol/L in the EDURANT group, and -0.6 nmol/L in the efavirenz group. At Week 96, the mean change from baseline in ACTH-stimulated cortisol levels was lower in the EDURANT group (+18.4 \pm 8.36 nmol/L) than in the efavirenz group (+54.1 \pm 7.24 nmol/L). Mean values for both basal and ACTH-stimulated cortisol values at Week 96 were within the normal range (>248nmol/L for basal and >500 nmol/L for stimulated values respectively). Overall, there were no serious adverse events, deaths, or treatment discontinuations that could clearly be attributed to adrenal insufficiency.

Serum creatinine

In the pooled Phase III trials, serum creatinine increased minimally over 96 weeks of treatment with EDURANT. In the overall population, small mean increases from baseline in serum creatinine values were observed at the first on treatment assessment (week 2) for the rilpivirine-treated patients, which remained relatively stable until week 24 when further mean increases from

baseline were observed until Week 96 (ranging from 5.3 μ mol/L at week 2 to a maximum mean increase from baseline of 9.7 μ mol/L at Week 96). For efavirenz-treated patients, serum creatinine values fluctuated around baseline up to Week 48 with a maximum mean increase from baseline of 3.5 μ mol/L at Week 96. In patients who entered the trial with mild or moderate renal impairment, the serum creatinine increase observed was similar to that seen in patients with normal renal function. These changes are not considered to be clinically relevant and no subject discontinued treatment due to increases in serum creatinine. Creatinine increases were comparable by background N(t)RTIs.

<u>Serum lipids</u>

Changes from baseline in total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides are presented in Table 5. The mean changes from baseline were smaller in the EDURANT arm versus the efavirenz arm. The impact of such findings has not been demonstrated.

Table 5: Lipid values, mean change from baseline [#]											
	Po	Pooled data from the week 96 analysis of the Phase III ECHO and THRIVE Trials									
		rilpiv	irine + BR			efavir	enz + BR				
	Ν	Baseline	Wee	k 96	Ν	Baseline	Wee	k 96			
Mean		Mean (mmol/L)	Mean (mmol/L)	Mean change* (mmol/L)		Mean (mmol/L)	Mean (mmol/L)	Mean change* (mmol/L)			
Total cholesterol (fasted) [†]	546	4.2	4.3	0.1	507	4.1	4.8	0.7			
HDL-cholesterol (fasted) [†]	545	1.1	1.2	0.1	505	1.0	1.3	0.3			
LDL-cholesterol (fasted) [†]	543	2.5	2.5	0.0	503	2.5	2.8	0.4			
Triglycerides (fasted) [†]	546	1.4	1.3	-0.1	507	1.5	1.6	0.1			

N=number of patients per treatment group

The change from baseline is the mean of within-patient changes from baseline for patients with both baseline and week 96 values.

[†] p-value < 0.001, Wilcoxon rank-sum test for treatment comparison of change from baseline

[#] Excludes subjects who received lipid lowering agents during the treatment period

Immune reconstitution inflammatory syndrome

In HIV infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise (immune reconstitution inflammatory syndrome) (see section 4.4 Special Warnings and Precautions for Use). Autoimmune disorders such as Graves' disease and autoimmune hepatitis have also been reported in the context of immune reconstitution inflammatory syndrome (see section 4.4 Special Warnings and Precautions for Use).

Additional information on special populations

Patients co-infected with hepatitis B and/or hepatitis C virus

In patients co-infected with hepatitis B or C virus receiving EDURANT, the incidence of hepatic enzyme elevation was higher than in patients receiving EDURANT who were not co-infected. This observation was the same in the efavirenz arm. The pharmacokinetic exposure of rilpivirine in co-infected patients was comparable to that in patients without co-infection.

Reporting suspected adverse reactions

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at <u>https://www.tga.gov.au/reporting-problems</u>.

4.9 OVERDOSE

There is no specific antidote for overdose with EDURANT. Human experience of overdose with rilpivirine is limited. Treatment of overdose with rilpivirine consists of general supportive measures including monitoring of vital signs and ECG (QT interval) as well as observation of the clinical status of the patient. Since rilpivirine is highly bound to plasma protein, dialysis is unlikely to result in significant removal of the active substance.

It is advisable to contact the Poison Information Centre (telephone 131126) for advice on the management of overdose.

PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

Mechanism of action

Rilpivirine is a diarylpyrimidine non-nucleoside reverse transcriptase inhibitor (NNRTI) of human immunodeficiency virus type-1 (HIV-1). Rilpivirine activity is mediated by non competitive inhibition of HIV-1 reverse transcriptase (RT). Rilpivirine does not inhibit the human cellular DNA polymerases α , β and γ .

Clinical trials

The evidence of efficacy of rilpivirine is based on the analyses of 96 week data from 2 randomised, double-blinded, active-controlled, Phase III trials TMC278-C209 (ECHO) and TMC278-C215 (THRIVE). The trials were identical in design, with the exception of the background regimen (BR). At 96 weeks, the virologic response rate [confirmed undetectable viral load (< 50 HIV-1 RNA copies/mL)] according to the time to loss of virologic response (TLOVR) algorithm was evaluated in patients receiving rilpivirine 25 mg q.d. in addition to a BR versus patients receiving efavirenz 600 mg q.d. in addition to a BR. The TLOVR imputation algorithm was used to define confirmed virologic response i.e., two consecutive viral load values below the threshold are needed to count as a response. Non-responders or failures were defined as those patients who never responded i.e. never achieved 2 consecutive viral load values of < 50 copies/mL, or who were a rebounder (patients responded, then has two consecutive viral load values of so copies/mL), or discontinued prematurely.

Antiretroviral treatment-naïve HIV-1 infected patients were enrolled who had a plasma HIV-1 RNA \geq 5000 copies/mL and were screened for susceptibility to N(t)RTIs and for absence of specific NNRTI RAMs. In ECHO, the BR was fixed to the N(t)RTIs, tenofovir disoproxil fumarate plus emtricitabine. In THRIVE, the BR consisted of 2 investigator-selected N(t)RTIs: tenofovir disoproxil fumarate plus emtricitabine <u>or</u> zidovudine plus lamivudine <u>or</u> abacavir plus lamivudine. In ECHO, randomisation was stratified by screening viral load. In THRIVE, randomisation was stratified by screening viral load.

This analysis included 690 patients in ECHO (346 on rilpivirine and 344 on efavirenz, respectively) and 678 patients in THRIVE (340 on rilpivirine and 338 on efavirenz, respectively) who had completed 96 weeks of treatment or discontinued earlier.

In the pooled analysis for ECHO and THRIVE, demographics and baseline characteristics were balanced between the rilpivirine arm and the efavirenz arm. Table 6 displays selected demographic and baseline disease characteristics of the patients in the rilpivirine and efavirenz arms. 53.3% of patients in the rilpivirine arm and 48.2% of patients in the efavirenz arm were in the \leq 100,000 copies/mL baseline viral load category. The proportion of patients with baseline viral load > 100,000 copies/mL was 46.7% and 51.8% in the rilpivirine arm and efavirenz arm, respectively.

Table 6: Demographic and baseline disease characteristics of antiretroviral treatment-naïve HIV-1 infected adult patients in the ECHO and THRIVE trials (pooled analysis)					
	Pooled data from the ECHO and THRIVE trials				
	rilpivirine + BR efavirenz + BR				
	N=686	N=682			

Demographic characteristics		
Median Age, years (range)	36 (18-78)	36 (19-69)
Sex		
Male	76%	76%
Female	24%	24%
Race		
White	61%	60%
Black/African American	24%	23%
Asian	11%	14%
Other	2%	2%
Not allowed to ask per local regulations	1%	1%
Baseline disease characteristics		
Median baseline plasma HIV-1	5.0	5.0
RNA (range), log ₁₀ copies/mL	(2-7)	(3-7)
Median baseline plasma HIV-1	90,450.0	104,500.0
RNA (range), copies/mL	(156 – 20,800,000)	(1,010 – 4,550,000)
Median baseline CD4+ cell count	249	260
(range), x 10 ⁶ cells/l	(1-888)	(1-1137)
Percentage of patients with:		
hepatitis B/C virus co-infection	7.3%	9.5%
Percentage of patients with the		
following background regimens:		
tenofovir disoproxil fumarate		
plus emtricitabine	80.2%	80.1%
zidovudine plus lamivudine	14.7%	15.1%
abacavir plus lamivudine	5.1%	4.8%

BR=background regimen

Table 7 below shows the efficacy results at 48 weeks and at 96 weeks for patients treated with EDURANT and patients treated with efavirenz from the pooled data from the ECHO and THRIVE trials. Similar efficacy for rilpivirine was seen in each trial demonstrating non-inferiority to efavirenz, i.e. estimated treatment difference (95%CI) was -0.4 (-5.9; 5.2) and 3.5 (-1.7; 8.8) at week 48 (primary) and -3.2 (-9.4; 3.1) and 2.4 (-3.6; 8.4) at week 96, in ECHO and THRIVE respectively.

The response rate (confirmed undetectable viral load < 50 HIV-1 RNA copies/mL) at week 96 was comparable between the rilpvirine arm and the efavirenz arm (77.6% for both arms, estimated treatment difference [95%CI] is -0.4% [-4.6%; 3.8%]). The incidence of virologic failure was higher in the rilpivirine arm than the efavirenz arm at week 96 (11.5% for rilpvirine and 5.9% for efavirenz); however, most of the virologic failures occurred within the first 48 weeks of treatment. Discontinuations due to adverse events were higher in the efavirenz arm at week 96 than the EDURANT arm. Most of these discontinuations occurred in the first 48 weeks of treatment.

Table 7: Virologic	Outcome of	Randomized	Treatment	in the	ECHO	and	THRIVE	Trials
(Pooled Analysis a	t Week 48 (pri	mary) and Wee	k 96; ITT-TL(OVR*)				

	Outcome at	Week 48	Outcome at Week 96		
n/N (%)	rilpivirine + BR N=686	efavirenz + BR N=682	rilpivirine + BR N=686	efavirenz + BR N=682	
Confirmed Undetectable Viral Load (< 50 HIV-1 RNA copies/mL) ^{§#}	578/686 (84.3)	561/682 (82.3)	532/686 (77.6)	529/682 (77.6)	
Virologic Failure [†]	62/686 (9.0)	33/682 (4.8)	(79/686) 11.5	40/682 (5.9)	
Death	1/686 (0.1)	3/682 (0.4)	(1/686) 0.1	6/682 (0.9)	
Discontinued due to adverse event (AE)	14/686 (2.0)	46/682 (6.7)	(26/686) 3.8	52/682 (7.6)	
Discontinued for non-AE reason [¶]	31/686 (4.5)	39/682 (5.7)	(48/686) 7.0	55/682 (8.1)	

N = number of patients per treatment group

* intent-to-treat time to loss of virologic response

Patients achieved virologic response (two consecutive viral loads < 50 copies/mL) and maintained it through week 48/96.
 Estimated difference of response rates (95% CI) at week 48: 1.6% (-2.2%; 5.3%) and at week 96: -0.4% (-4.6%; 3.8%); both p-value < 0.0001 (non-inferiority at 12% margin) from logistic regression model, including stratification factors and study.

[†] Includes patients who were rebounder (confirmed viral load ≥ 50 copies/mL after being responder) or who were never suppressed (no confirmed viral load < 50 copies/mL, either ongoing or discontinued due to lack or loss of efficacy).</p>

e.g. lost to follow-up, non-compliance, withdrew consent

The mean change from baseline in CD4+ cell count was $+192 \times 10^6$ cells/l in the rilpivirine arm and $+176 \times 10^6$ cells/l in the efavirenz arm in the pooled analysis of the ECHO and THRIVE trials [estimated treatment difference (95% CI): 17.9 (2.1; 33.6)] at week 48. At week 96, the mean change from baseline in CD4+ cell count was $+228 \times 10^6$ cells/l in the EDURANT arm (n=685) and $+219 \times 10^6$ cells/l in the efavirenz arm (n=682) in the pooled analysis of the ECHO and THRIVE trials [estimated treatment difference (95% CI): 11.3 (-6.8; 29.4)].

A subgroup analysis of the virologic response (< 50 HIV-1 RNA copies/mL) at 48 and 96 weeks and virologic failure by baseline viral load, CD4 count and by background NRTIs (pooled data from the ECHO and THRIVE trials) is presented in Table 8.

Table 8: Virolog virologic failure (pooled data free	e by baseli	ne viral load,	by bas	eline CD4 co					
		Outcome at Week 48			Outcome at Week 96				
		EDURANT + BR N=686		Efavirenz + BR N=682		EDURANT + BR N=686		Efavirenz + BR N=682	
	N	n (%)	Ν	n (%)	Ν	n (%)	Ν	n (%)	
Proportion of	patients w	ith HIV-1 RNA	A < 50 c	opies/mĹ at	week 48	* and at wee	ek 96* b	y baseline	
•	-	plasr	na viral	load (copies	/mL)			-	
≤ 100,000	368	332	330	276	368	309	329	263	
		(90.2%)		(83.6%)		(84.0%)		(79.9%)	
> 100,000	318	246	352	285	318	223	353	266	
		(77.4%)		(81.0%)		(70.1%)		(75.4%)	
Virologic Failure [†] by baseline plasma viral load (copies/mL)									
≤ 100,000	368	14	330	11	368	21	329	12	
		(3.8%)		(3.3%)		(5.7%)		(3.6%)	
> 100,000	318	48	352	22	318	58	353	28	
		(15.1%)		(6.3%)		(18.2%)		(7.9%)	
Proportion of patients with HIV-1 RNA < 50 copies/mL at week 48* and at week 96* by baseline CD4 count (x 10 ⁶ cells/l)									
< 50	34	20	36	29	34	19	36	25	
		(58.8%)		(80.6%)		(55.9%)		(69.4%)	
≥ 50 - < 200	194	156	175	143	194	138	175	131	
		(80.4%)		(81.7%)		(71.1%)		(74.9%)	

≥ 200 - < 350		313	272 (86.9%)	307	253 (82.4%)	313	252 (80.5%)	307	244 (79.5%)
≥ 350		144	130 (90.3%)	164	136 (82.9%)	144	123 (85.4%)	164	129 (78.7%)
Virologic Fa	Virologic Failure [†] by baseline CD4 count (x 10 ⁶ cells/l)								
< 50		34	6 (17.6%)	36	1 (2.8%)	34	6 (17.6%)	36	4 (11.1%)
≥ 50-< 200		194	27 (13.9%)	175	14 (8.0%)	194	37 (19.1%)	175	14 (8.0%)
≥ 200-< 350		313	21 (6.7%)	307	14 (4.6%)	313	26 (8.3%)	307	15 (4.9%)
≥ 350		144	8 (5.6%)	164	4 (2.4%)	144	10 (6.9%)	164	7 (4.3%)
Proportion o N(t)RTI	of patio	ents wi	th HIV-1 RNA ·	< 50 co	pies/mL at we	ek 48*	and at week	96* by l	background
tenofovir disoproxil fumarate emtricitabine	plus	550	459 (83.5%)	546	450 (82.4%)	550	423 (76.9%)	546	422 (77.3%)
zidovudine lamivudine	plus	101	88 (87.1%)	103	83 (80.6%)	101	82 (81.2%)	103	79 (76.7%)
abacavir Iamivudine	plus	35	31 (88.6%)	33	28 (84.8%)	35	27 (77.1%)	33	28 (84.8%)

N=number of patients per treatment group

n=number of observations

* Imputations according to the TLOVR algorithm.

† Includes patients who were rebounder (confirmed viral load ≥ 50 copies/mL after being responder) or who were never suppressed (no confirmed viral load < 50 copies/mL, either ongoing or discontinued due to lack or loss of efficacy).</p>

At week 96, response rates (< 50 copies/mL [TLOVR]) in the pooled Phase III trial population were 84.0% in the EDURANT arm and 79.9% in the efavirenz arm in patients with a baseline viral load \leq 100,000 copies/mL versus 70.1% and 75.4%, respectively, in patients with a baseline viral load > 100,000 copies/mL. The proportion of virologic failures according to TLOVR in the pooled Phase III trial population was 5.7% in the EDURANT arm and 3.6% in the efavirenz arm, for patients with a baseline viral load \leq 100,000 copies/mL. The proportion of virologic failures arm and 3.6% in the efavirenz arm, for patients with a baseline viral load \leq 100,000 copies/mL. The proportion of virologic failures arm and 3.6% in the efavirenz arm, for patients with a baseline viral load \leq 100,000 copies/mL. The proportion of virologic failures was higher for patients with a baseline viral load > 100,000 copies/mL, especially in the EDURANT arm (18.2% EDURANT-treated patients vs. 7.9% efavirenz-treated patients).

The incidence of emergence of N(t)RTI and NNRTI RAMs in the virologic failures (according to the resistance analysis criteria) was lower in the \leq 100,000 copies/mL category than in the > 100,000 copies/mL category. This difference was observed in both treatment groups but with a lower incidence of emerging mutations in the efavirenz arm. This difference in incidence of emerging mutations between treatment groups was greater for N(t)RTI mutations. At week 48, among patients with baseline viral load \leq 100,000 copies/mL (16 patients in the rilpivirine arm and 12 patients in the efavirenz arm), 7 and 6 rilpivirine virologic failures and 2 and 5 efavirenz virologic failures had emerging N(t)RTI RAMs and NNRTI RAMs, respectively. Among patients with baseline viral load > 100,000 copies/mL (46 patients in the rilpivirine arm and 16 patients in the efavirenz arm), 35 and 33 rilpivirine virologic failures and 7 and 10 efavirenz virologic failures had emerging N(t)RTI RAMs, respectively. The less frequent emergence of N(t)RTI and NNRTI RAMs in the \leq 100,000 copies/mL category, as compared to the > 100,000 copies/mL category of both treatment groups, as well as the lower incidence of emerging N(t)RTI mutations in efavirenz virologic failures as compared to rilpivirine virologic failures were confirmed in the week 96 pooled Phase III analyses.

Study TMC278-C204 was a randomised, active-controlled, Phase IIb trial in antiretroviral treatment-naïve HIV-1 infected adult patients consisting of 2 parts: an initial partially blinded dose-finding part [rilpivirine doses blinded] up to 96 weeks, followed by a long-term, open label part. In the open label part of the trial, patients originally randomised to one of the 3 doses of rilpivirine were all treated with rilpivirine 25 mg once daily in addition to a BR, once the dose for

the Phase III studies was selected. Patients in the control arm received efavirenz 600 mg once daily in addition to a BR in both parts of the study. The BR consisted of 2 investigator-selected N(t)RTIs: zidovudine plus lamivudine <u>or</u> tenofovir disoproxil fumarate plus emtricitabine.

Study TMC278-C204 enrolled 368 HIV-1 infected treatment-naïve adult patients who had a plasma HIV-1 RNA \geq 5000 copies/mL, previously received \leq 2 weeks of treatment with an N(t)RTI or protease inhibitor, had no prior use of NNRTIs, and were screened for susceptibility to N(t)RTI and for absence of specific NNRTI RAMs.

At 96 weeks, the proportion of patients with < 50 HIV-1 RNA copies/mL receiving rilpivirine 25 mg (N=93) compared to patients receiving efavirenz (N=89) was 76% and 71%, respectively. The mean increase from baseline in CD4+ counts was 146 x 10^6 cells/l in patients receiving rilpivirine 25 mg and 160 x 10^6 cells/l in patients receiving efavirenz.

Of those patients who were responders at week 96, 151/204 (74%) of patients receiving rilpivirine remained with undetectable viral load (< 50 HIV-1 RNA copies/mL) at week 240 compared to 51/63 (81%) of patients receiving efavirenz. There were no safety concerns identified in the week 240 analyses.

<u>Pregnancy</u>

Rilpivirine in combination with a background regimen was evaluated in a clinical trial of 19 pregnant women during the second and third trimesters, and postpartum. The pharmacokinetic data demonstrate that total exposure (AUC) to rilpivirine as a part of an antiretroviral regimen was approximately 30% lower during pregnancy compared with postpartum (6-12 weeks). Virologic response was preserved throughout the trial period. No mother to child transmission occurred in all 10 infants born to the mothers who completed the trial and for whom the HIV status was available. Out of 12 subjects completing the study, 10 were suppressed and the other 2 had increased viral load likely due to suboptimal adherence. Rilpivirine was well tolerated during pregnancy and postpartum. There were no new safety findings compared with the known safety profile of rilpivirine in HIV-1 infected adults.

Antiviral activity in vitro

Rilpivirine exhibited activity against laboratory strains of wild type HIV-1 in an acutely infected T-cell line with a median EC_{50} value for HIV-1/IIIB of 0.73 nM (0.27 ng/mL). Although rilpivirine demonstrated limited *in vitro* activity against HIV-2 with EC_{50} values ranging from 2,510 to10,830 nM (920 to 3,970 ng/mL), treatment of HIV-2 infection with rilpivirine is not recommended in the absence of clinical data.

Rilpivirine also demonstrated antiviral activity against a broad panel of HIV-1 group M (subtype A, B, C, D, F, G, H) primary isolates with EC_{50} values ranging from 0.07 to 1.01 nM (0.03 to 0.37 ng/mL) and group O primary isolates with EC_{50} values ranging from 2.88 to 8.45 nM (1.06 to 3.10 ng/mL).

Rilpivirine showed additive antiviral activity in combination with the N(t)RTIs: abacavir, didanosine, emtricitabine, stavudine and tenofovir; the protease inhibitors: amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tipranavir; the NNRTIs: efavirenz, etravirine and nevirapine; the fusion inhibitor enfuvirtide; and the entry inhibitor maraviroc. Rilpivirine shows additive to synergistic antiviral activity in combination with the NRTIs lamivudine and zidovudine, and the integrase inhibitor raltegravir.

Resistance

<u>In cell culture</u>

Rilpivirine-resistant strains were selected in cell culture starting from wild type HIV-1 of different origins and subtypes as well as NNRTI-resistant HIV-1. The most commonly observed amino acid substitutions that emerged included: L100I, K101E, V108I, E138K, V179F, Y181C, H221Y, F227C and M230I.

Resistance to rilpivirine was determined as a fold change in EC_{50} value (FC) above the biological cut-off (BCO) of the assay.

In treatment-naïve patients

For the resistance analysis, a broader definition of virologic failure was used than in the primary efficacy analysis. The definition of virologic failure used in the efficacy analysis of the Phase III studies was based on the time to loss of virologic failure (TLOVR) algorithm (see section 5.1 Pharmacodynamic Properties, Clinical Trials).

The broader definition of virologic failure used in the resistance analysis of the Phase III studies included patients who were defined as rebounders (had 2 consecutive viral load measurements < 50 copies/mL, followed by 2 consecutive viral load values \geq 50 copies/mL), patients who stopped treatment while not suppressed (had 2 consecutive viral load measurements < 50 copies/mL and stopped treatment with a last observed on-treatment viral load value of \geq 50 copies/mL) or patients who never suppressed (no confirmed viral load measurements < 50 copies/mL) or patients who never suppressed (no confirmed viral load measurements < 50 copies/mL and an increase in viral load \geq 0.5 log₁₀ copies/mL above the nadir, regardless of time of failure and reason for discontinuation).

In the week 48 pooled resistance analysis from the Phase III trials, 62 (of a total of 72) virologic failures in the rilpivirine arm had resistance data at baseline and time of failure as compared to 28 (of a total of 39) virologic failures in the efavirenz arm. In this analysis, the amino acid substitutions associated with NNRTI resistance that developed in at least 2 rilpivirine virologic failures were: V90I, K101E, E138K, E138Q, V179I, Y181C, V189I, H221Y and F227C. The most common mutations were the same in the week 48 and week 96 analyses. In the trials, the presence of the substitutions V90I and V189I, at baseline, did not affect response. The E138K substitution emerged most frequently during the rilpivirine treatment, commonly in combination with the M184I substitution.

More patients who failed virologically on EDURANT than who failed virologically on efavirenz developed lamivudine/emtricitabine associated resistance.

In the week 96 pooled resistance analysis, lower rates of virologic failure were observed in the second 48 weeks than in the first 48 weeks of treatment. From the week 48 to the week 96 analysis, 24 (3.5%) and 14 (2.1%) additional virologic failures occurred in the rilpivirine and efavirenz arm, respectively. Of these virologic failures, 9 out of 24 and 4 out of 14 were in subjects with a baseline viral load < 100,000 copies/mL, respectively.

Considering all of the available *in vitro* and *in vivo* data, the following amino acid substitutions, when present at baseline, are likely to affect the activity of rilpivirine: K101E, K101P, E138A, E138G, E138K, E138Q, E138R, V179L, Y181C, Y181I, Y181V, Y188L, H221Y, F227C, M230I and M230L.

Cross resistance

Site directed NNRTI mutant virus

In a panel of 67 HIV-1 recombinant laboratory strains with one amino acid substitution at RT positions associated with NNRTI resistance, including the most commonly found K103N and Y181C, rilpivirine showed antiviral activity against 64 (96%) of these strains. The single amino acid substitutions associated with a loss of susceptibility to rilpivirine were: K101P, Y181I and Y181V. The K103N substitution did not result in reduced susceptibility to rilpivirine by itself, but the combination of K103N and L100I resulted in a 7-fold reduced susceptibility to rilpivirine.

Recombinant clinical isolates

Rilpivirine retained sensitivity (FC \leq BCO) against 62% of 4786 HIV-1 recombinant clinical isolates resistant to efavirenz and/or nevirapine.

Treatment naïve HIV 1 infected patients

In the week 48 pooled analysis of the Phase III trials ECHO and THRIVE, 31 of the 62 patients with virologic failure on rilpivirine with phenotypic resistance data lost susceptibility to rilpivirine. Of these, 28 were resistant to etravirine, 27 to efavirenz, and 14 to nevirapine. These cross-resistance findings were confirmed in the week 96 pooled analyses of the Phase III clinical trials.

In the week 96 pooled resistance analysis of the Phase III trials (ECHO and THRIVE), 42 out of 86 subjects with virologic failure on rilpivirine showed treatment-emergent resistance to rilpivirine (genotypic analysis). In these patients, phenotypic cross-resistance to other NNRTIs was noted as follows: etravirine 32/42, efavirenz 30/42, and nevirapine 16/42. In patients with a baseline viral load \leq 100,000 copies/mL, 9 out of 27 patients with virologic failure on rilpivirine showed treatment-emergent resistance to rilpivirine (genotypic analysis), with the following frequency of phenotypic cross-resistance: etravirine 4/9, efavirenz 3/9, and nevirapine 1/9. In rilpivirine virologic failures with resistance to rilpivirine (genotypic analysis), phenotypic cross-resistance to etravirine, efavirenz, and nevirapine was observed in, respectively, 28, 27, and 15 of 30 patients with baseline viral load > 100,000 copies/mL.

Effects on electrocardiogram

The effect of rilpivirine at the recommended dose of 25 mg q.d. on the QTcF interval was evaluated in a randomised, placebo and active (moxifloxacin 400 mg once daily) controlled crossover study in 60 healthy adults, with 13 measurements over 24 hours at steady state. Rilpivirine at the recommended dose of 25 mg q.d. is not associated with a clinically relevant effect on QTc.

When supratherapeutic doses of 75 mg q.d. and 300 mg q.d. of rilpivirine were studied in healthy adults, the maximum mean time matched (95% upper confidence bound) differences in QTcF interval from placebo after baseline correction were 10.7 (15.3) and 23.3 (28.4) ms, respectively. Steady state administration of rilpivirine 75 mg q.d. and 300 mg q.d. resulted in a mean C_{max} approximately 2.6 fold and 6.7 fold, respectively, higher than the mean steady state C_{max} observed with the recommended 25 mg q.d. dose of rilpivirine.

5.2 PHARMACOKINETIC PROPERTIES

The pharmacokinetic properties of rilpivirine have been evaluated in adult healthy subjects and in adult antiretroviral treatment naïve HIV 1 infected patients. Exposure to rilpivirine was generally lower in HIV-1 infected patients than in healthy subjects.

Absorption

After oral administration, the maximum plasma concentration of rilpivirine is generally achieved within 4-5 hours. The absolute bioavailability of rilpivirine is unknown.

Effect of food on absorption

The exposure to rilpivirine was approximately 40% lower when rilpivirine was taken in a fasted condition as compared to a normal caloric meal (533 kcal) or high fat high caloric meal (928 kcal). When rilpivirine was taken with only a protein rich nutritional drink, exposures were 50% lower than when taken with a meal (see section 4.2 Dose and Method of Administration).

Distribution

Rilpivirine is approximately 99.7% bound to plasma proteins *in vitro*, primarily to albumin. The distribution of rilpivirine into compartments other than plasma (e.g., cerebrospinal fluid, genital tract secretions) has not been evaluated in humans.

Metabolism

In vitro experiments indicate that rilpivirine primarily undergoes oxidative metabolism mediated by the cytochrome P450 (CYP) 3A system. It is possible that different populations of patients have faster or slower rilpivirine metabolism because of the various isoenzymes within the CYP3A system.

Excretion

The terminal elimination half-life of rilpivirine is approximately 45 hours. After single dose oral administration of ¹⁴C rilpivirine, on average 85% and 6.1% of the radioactivity could be retrieved in faeces and urine, respectively. In faeces, unchanged rilpivirine accounted for on average 25% of the administered dose. Only trace amounts of unchanged rilpivirine (< 1% of dose) were detected in urine.

Additional information on special populations

Paediatric population

The pharmacokinetics of rilpivirine in paediatric patients (<18 years of age) have not been established.

<u>Elderly</u>

Population pharmacokinetic analysis in HIV infected patients showed that rilpivirine pharmacokinetics are not different across the age range (18 to 78 years, with only 2 patients aged above 65 years) evaluated. No dose adjustment of rilpivirine is required in elderly patients. EDURANT should be used with caution in this population.

<u>Gender</u>

Population pharmacokinetic analysis in HIV infected patients showed no clinically relevant differences in the pharmacokinetics of rilpivirine between men and women.

<u>Race</u>

Population pharmacokinetic analysis of rilpivirine in HIV infected patients indicated that race had no clinically relevant effect on the exposure to rilpivirine.

<u>Hepatic impairment</u>

There is limited information regarding the use of EDURANT in patients with mild or moderate hepatic impairment, resulting in unexpected variability in the available data.

Rilpivirine is primarily metabolised and eliminated by the liver. In a study comparing 8 patients with mild hepatic impairment (Child Pugh score A) to 8 matched controls, and 8 patients with moderate hepatic impairment (Child Pugh score B) to 8 matched controls. The mean steady-state exposure to rilpivirine was higher in patients with mild hepatic impairment (27% higher for C_{max} and 47% higher for AUC) than in healthy controls. However, rilpivirine exposure in patients with moderate hepatic impairment (5% lower for C_{max} and 5% higher for AUC) was similar to healthy controls. The mean apparent elimination half-life of rilpivirine was longer in patients with mild (81 hours versus 61 hours respectively) and moderate (91 hours versus 56 hours, respectively) hepatic impairment. No dose adjustment is suggested but caution is advised in patients with moderate hepatic impairment. Rilpivirine has not been studied in patients with severe hepatic impairment (child Pugh score C). Therefore, EDURANT is not recommended in patients with severe hepatic impairment (see sections 4.4 Special Warnings and Precautions for Use and 4.2 Dose and Method of Administration).

Hepatitis B and/or hepatitis C virus co infection

Population pharmacokinetic analysis indicated that hepatitis B and/or C virus co infection had no clinically relevant effect on the exposure to rilpivirine.

<u>Renal impairment</u>

The pharmacokinetics of rilpivirine have not been studied in patients with renal insufficiency. Renal elimination of rilpivirine is negligible. EDURANT has mainly been studied in patients with normal renal function. No dose adjustment is required for patients with mild or moderate renal impairment. In patients with severe renal impairment or end stage renal disease, EDURANT should be used with caution. In patients with severe renal impairment or end stage renal disease, the combination of EDURANT with a strong CYP3A inhibitor (e.g., ritonavir boosted HIV protease inhibitor) should only be used if the benefit outweighs the risk (see section 4.2 Dose and Method of Administration). As rilpivirine is highly bound to plasma proteins, it is unlikely that it will be significantly removed by haemodialysis or peritoneal dialysis.

Pregnancy and postpartum

The exposure to total rilpivirine after intake of rilpivirine 25 mg once daily as part of an antiretroviral regimen was lower during pregnancy (similar for the 2nd and 3rd trimester) compared with postpartum (see Table 9). The decrease in unbound (i.e., active) rilpivirine pharmacokinetic parameters during pregnancy compared to postpartum was less pronounced than for total rilpivirine.

In women receiving rilpivirine 25 mg once daily during the 2nd trimester of pregnancy, mean intraindividual values for total rilpivirine C_{max}, AUC_{24h} and C_{min} values were, respectively, 21%, 29% and 35% lower as compared to postpartum; during the 3rd trimester of pregnancy, Cmax, AUC24h and C_{min} values were, respectively, 20%, 31% and 42% lower as compared to postpartum.

Table 9: Pharmacokinetic Results of Total Rilpivirine After Administration of Rilpivirine 25 mg Once Daily as Part of an Antiretroviral Regimen, During the 2 nd Trimester of Pregnancy,							
the 3 rd Trimester of Pregnancy and Postpartum							
Pharmacokinetics of total	Postpartum	2 nd Trimester	3 rd Trimester				
rilpivirine	(6-12 Weeks)	of pregnancy	of pregnancy				
(mean \pm SD, t _{max} : median [range])	(n=11)	(n=15)	(n=13)				
C _{min} , ng/mL	84.0 ± 58.8	54.3 ± 25.8	52.9 ± 24.4				
C _{max} , ng/mL	167 ± 101	121 ±45.9	123 ± 47.5				
t _{max} , h	4.00 (2.03-25.08)	4.00 (1.00-9.00)	4.00 (2.00-24.93)				
AUC _{24h} , ng.h/mL	2714 ± 1535	1792 ± 711	1762 ± 662				

5.3 PRECLINICAL SAFETY DATA

Genotoxicity

Rilpivirine has tested negative in the in vitro Ames reverse mutation assay and in vitro clastogenicity mouse lymphoma assay, tested in the absence and presence of a metabolic activation system. Rilpivirine did not induce chromosomal damage in the in vivo micronucleus test in mice.

Carcinogenicity

Rilpivirine was evaluated for carcinogenic potential by oral gavage administration to mice and rats up to 104 weeks. Daily doses of 20, 60 and 160 mg/kg/day were administered to mice and doses of 40, 200, 500 and 1500 mg/kg/day were administered to rats. An increase in the incidences of hepatocellular adenomas and carcinomas was observed in mice and rats. An increase in the incidences of follicular cell adenomas and/or carcinomas in the thyroid gland was observed in rats. Administration of rilpivirine did not cause a statistically significant increase in the incidence of any other benign or malignant neoplasm in mice or rats. The observed hepatocellular findings in mice and rats are considered to be rodent specific, associated with liver enzyme induction. A similar mechanism does not exist in humans; hence, these tumors are not relevant for humans. The follicular cell findings are considered to be rat specific, associated with increased clearance of thyroxine and are not considered to be relevant for humans. At the lowest tested doses in the carcinogenicity studies, the systemic exposures (based on AUC) to rilpivirine were 21 fold (mice) and 3 fold (rats), relative to those observed in humans at the recommended dose (25 mg q.d.).

6. PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS

Lactose monohydrate (each tablet contains 56 mg lactose monohydrate)

Croscarmellose sodium

Povidone

Polysorbate 20

Silicified microcrystalline cellulose (a combination of microcrystalline cellulose and silicon dioxide)

Magnesium stearate

Hypromellose

Titanium dioxide

Macrogol 3000

Glycerol triacetate.

6.2 INCOMPATIBILITIES

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 SHELF LIFE

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 SPECIAL PRECAUTIONS FOR STORAGE

Store below 30°C. Store in the original bottle. Protect from light.

6.5 NATURE AND CONTENTS OF CONTAINER


EDURANT tablets are provided in a high density polyethylene (HDPE) bottle with a polypropylene (PP) child resistant closure and induction seal liner. One bottle contains 30 tablets.

6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 PHYSIOCHEMICAL PROPERTIES

Chemical structure:



CAS No.: 700361-47-3 Molecular formula: C₂₂H₁₈N₆.HCl

Molecular weight: 402.88

The chemical name of rilpivirine is 4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino-2-pyrimidinyl]amino]benzonitrile monohydrochloride.

Rilpivirine hydrochloride is a white to off-white powder. Rilpivirine hydrochloride is practically insoluble in water over a wide pH range, its pKa is 5.6 (pyrimidine moiety) and log P between 1-octanol and a phosphate solution (pH 7.0) is 4.86 (at 21°C).

7. MEDICINE SCHEDULE (POISON STANDARD)

S4 – Prescription Only Medicine

8. SPONSOR

JANSSEN-CILAG Pty Ltd 1-5 Khartoum Rd Macquarie Park NSW 2113 Australia

NZ Office: Auckland New Zealand

9. DATE OF FIRST APPROVAL

23 December 2011

10. DATE OF REVISION

16 January 2025

SUMMARY TABLE OF CHANGES

Section	Summary of changes				
4.4	Deletion of text regarding antiretroviral therapy not having been proven to prevent the HIV transmission to others through blood or sexual contact.				
5.3	Deletion of text regarding chromosomal aberration assay.				